A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab

Conditions:   Non Small Cell Lung Cancer (NSCLC);   Urothelial Carcinoma (UC);   Squamous Cell Carcinoma of the Head and Neck (SCCHN);   Metastatic Breast Cancer (mBC);   Castration-resistant Prostate Cancer (CRPC)
Interventions:   Drug: PT-112;   Biological: avelumab
Sponsors:   Phosplatin Therapeutics;   Pfizer;   EMD Serono
Not yet recruiting

http://ift.tt/2G9Mcxj